Recent advances in the systemic treatment landscape have considerably improved disease control in the metastatic setting and led to better oncological outcomes, particularly in human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) breast cancer [6,7,8]. This evidence concerns the gene ERBB2 and breast cancer.